Many women with early-stage breast cancer may be able to skip chemotherapy, according to a new study.
A gene test called “Oncotype D-X” has been guiding doctors for years on whether women need chemo if they have receptor-positive, her-2negative, early-stage breast cancer that hasn’t spread.
A low test score means patients can forgo the treatment – as well as its toxic side effects – while a high score means women would greatly benefit.
For years – doctors were unsure how to treat women who fell in the middle range of the scoring system.
Now, research on more than 10,000 patients finds those mid-range women can safely be spared chemotherapy – without affecting survival.
Experts say these findings will change treatment practices immediately.